According to their patient data, EAF2 and PTEN are downregulated concurrently in >50% of advanced human prostate cancer (Gleason scores of 8–9) specimens, indicating that EAF2 and PTEN co-downregulation represents poor prognosis (Ai et al., 2014). Here, EAF2 is linked to prostate carcinoma.